Cundari Gianna Barbara, Feole Laura, Terranova Corrado, De Cicco Nardone Carlo, Montera Roberto, Luvero Daniela, Guzzo Federica, Martinelli Arianna, Di Donato Violante, Angioli Roberto, Plotti Francesco
Research Unit of Gynaecology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy.
Department of Gynaecology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Cancers (Basel). 2025 Apr 27;17(9):1473. doi: 10.3390/cancers17091473.
: Serum biomarkers such as Carcinoma Antigen 125 (CA125) and Human Epididymis Protein 4 (HE4) are widely used in the diagnosis and prognosis of gynecological malignancies. Serum biomarkers such as CA125 and HE4 represent essential tools in improving early detection, risk stratification, and therapeutic decision-making for gynecological malignancies. However, their role in identifying uterine sarcomas remains debated. This systematic review and case series aims to examine the diagnostic and prognostic significance of CA125 and HE4 in uterine sarcomas. : A systematic review was performed on studies investigating serum CA125 and HE4 levels in uterine sarcomas. A case series of all uterine sarcomas treated at the Campus Bio-Medico Gynecology Unit of Rome from 2010 to 2020 was analyzed. : The analysis of the 11 selected studies allowed us to investigate the role of CA125 in uterine sarcomas. No studies analyzing the role of HE4 in monitoring the disease were found. A total of 16 patients with confirmed uterine leiomyosarcoma were included in our case series. : Neither CA125 nor HE4 can currently be considered definitive biomarkers for the diagnosis of uterine leiomyosarcomas. However, they may serve as useful adjuncts in the differential diagnosis between leiomyomas and leiomyosarcomas, particularly in reproductive-age patients.
血清生物标志物，如癌抗原125（CA125）和人附睾蛋白4（HE4），广泛应用于妇科恶性肿瘤的诊断和预后评估。CA125和HE4等血清生物标志物是改善妇科恶性肿瘤早期检测、风险分层和治疗决策的重要工具。然而，它们在识别子宫肉瘤中的作用仍存在争议。本系统评价和病例系列旨在探讨CA125和HE4在子宫肉瘤中的诊断和预后意义。：对研究子宫肉瘤血清CA125和HE4水平的研究进行了系统评价。分析了2010年至2020年在罗马生物医学大学校园妇科治疗的所有子宫肉瘤病例系列。：对11项选定研究的分析使我们能够研究CA125在子宫肉瘤中的作用。未发现分析HE4在监测疾病中作用的研究。我们的病例系列共纳入了16例确诊的子宫平滑肌肉瘤患者。：目前，CA125和HE4都不能被视为诊断子宫平滑肌肉瘤的确定性生物标志物。然而，它们可能作为平滑肌瘤和平滑肌肉瘤鉴别诊断的有用辅助手段，特别是在育龄患者中。
